1.Anti-melanogenic effects of black, green, and white tea extracts on immortalized melanocytes.
Young Chul KIM ; So Young CHOI ; Eun Ye PARK
Journal of Veterinary Science 2015;16(2):135-143
Tea contains polyphenols and is one of the most popular beverages consumed worldwide. Because most tyrosinase inhibitors that regulate melanogenesis are phenol/catechol derivatives, this study investigated the inhibitory effects of Camellia sinensis water extracts (CSWEs), including black tea, green tea, and white tea extracts, on melanogenesis using immortalized melanocytes. CSWEs inhibited melanin accumulation and melanin synthesis along with tyrosinase activity in a concentration-dependent manner. These inhibitory effects were superior to those of arbutin, a well-known depigmenting agent. The anti-melanogenic activity of black (fermented) tea was higher than that of a predominant tea catecholamine, epigallocatechin gallate. CSWEs, especially black tea extract, decreased tyrosinase protein levels in a concentration-dependent manner. These results suggest that the anti-melanogenic effect of CSWEs is mediated by a decrease in both tyrosinase activity and protein expression, and may be augmented by fermentation. Thus, CSWEs could be useful skin-whitening agents in the cosmetic industry.
Animals
;
Catechin/analogs & derivatives/metabolism
;
Cell Line
;
Melanins/*metabolism
;
Melanocytes/enzymology/*metabolism
;
Mice
;
Monophenol Monooxygenase/*metabolism
;
Plant Extracts/*pharmacology
;
Plant Leaves/chemistry
;
Tea/*chemistry
2.Giant cell tumor associated with aneurysmal bone cyst: five cases report.
Sung Joon KIM ; Il Yong CHOI ; Tai Seung KIM ; Kwang Hyun LEE ; Ye Soo PARK ; Eun Kyung HONG
The Journal of the Korean Orthopaedic Association 1991;26(3):1000-1005
No abstract available.
Aneurysm*
;
Bone Cysts*
;
Giant Cell Tumors*
;
Giant Cells*
3.Gender Differences in Cognitive Function of Schizophrenia Patients
Kyounghwan PARK ; Mal-Rey CHOI ; Ye-Eun SHIN ; Myeong-Il HAN
Korean Journal of Schizophrenia Research 2024;27(2):72-77
Objectives:
Cognitive impairment is a fundamental symptom of schizophrenia, an often-overlooked aspect of the disorder that has gained recent attention due to its direct relation with functional outcomes and implications for medical and social costs. This study aims to investigate gender differences in cognitive function among patients with schizophrenia using Korean Wechsler Adult Intelligence Scale-IV (K-WAIS-IV).
Methods:
Data were collected from inpatients and outpatients treated at Presbyterian Medical Center between January 1, 2019, and December 31, 2023. Patients diagnosed with schizophrenia underwent evaluation with the K-WAIS-IV. Multivariate analysis of variance was utilized to assess cognitive differences between men and women participants, while correlation analysis was performed to explore associations between cognitive performance and clinical data.
Results:
Among 101 candidates, 26 male and 26 female patients were selected for analysis of their K-WAIS-IV scores and clinical data. The results revealed no statistically significant differences in cognitive function between male and female patients concerning Full-Scale Intelligence Quotient (FSIQ) and the four index scores: Verbal Comprehension Index (VCI), Perceptual Reasoning Index (PRI), Working Memory Index (WMI), and Processing Speed Index (PSI). A trend indicating preserved verbal intelligence relative to performance intelligence was observed. Additionally, the VCI exhibited a positive correlation with age, while both FSIQ and PSI demonstrated positive correlations with years of education.
Conclusion
The findings of this investigation suggest that there are no significant differences in cognitive function between male and female patients with schizophrenia via K-WAIS-IV. Given the heterogeneity of the sample and potential limitations of the neurocognitive assessments employed, further research utilizing more targeted methodologies and sensitive measures is warranted.
4.Relationship between Functional Fitness and Break Response in Elderly Drivers: Comparison with Young Driver.
Ga Eun KIM ; Ye Eun CHOI ; Su Seong YANG ; Sun A KIM ; Young Sook BAE
Journal of Korean Physical Therapy 2018;30(5):187-192
PURPOSE: This study compared the functional fitness and brake response of elderly and young drivers to confirm the correlation between the functional fitness and brake response. METHODS: This study was a cross sectional observational design. Older drivers (>65age, n=21) and young adult drivers (20–40aged, n=20) were enrolled as subjects. The functional fitness of the subjects was measured using a senior fitness test consisting of a back scratch (BS), chair sit and reach (CSR), arm curl (AC), chair stand up (CSU), foot up and go (8-FUG), and 2-minute step (2-MS). The brake response used the virtual driving simulator to measure the brake reaction time (BRT) and braking distance (BD) according to the pedestrian protection and traffic signal compliance. RESULTS: The older drivers had a lower BS (p < 0.000), CSU (p=0.040), and 8-FUG (p=0.011) than the young adult drivers. BS and 8-FUG showed a significant positive correlation with the BRT and BD of pedestrian protection and traffic signal compliance. CSU showed a significant negative correlation with the BRT of pedestrian protection and traffic signal compliance. CONCLUSION: These findings suggest that the flexibility of the upper extremity, lower extremity strength, and agility are strongly correlated with the driving performance of elderly drivers.
Aged*
;
Arm
;
Compliance
;
Foot
;
Humans
;
Lower Extremity
;
Pliability
;
Reaction Time
;
Upper Extremity
;
Young Adult
5.Diagnostic Neuroimaging in Headache Patients: A Systematic Review and Meta-Analysis
Ye Eun JANG ; Eun Young CHO ; Hee Yea CHOI ; Sun Mi KIM ; Hye Youn PARK
Psychiatry Investigation 2019;16(6):407-417
OBJECTIVE: Neuroimaging in headache patients identifies clinically significant neurological abnormalities and plays an important role in excluding secondary headache diagnoses. We performed a systematic review and meta-analysis of the existing guidelines and studies surrounding neuroimaging in headache patients. METHODS: The research question involved determining the prevalence of detecting clinically significant neurological abnormalities using neuroimaging in patients suspected of primary headache. Searches of the PubMed and Embase databases were conducted on English-language studies published from 1991 to 2016, and the reference lists of the retrieved articles were also checked manually. All headache subtypes and patients aged ≥15 years were included in the analysis. RESULTS: Ten studies met the selection criteria. The pooled prevalence of detecting clinically significant abnormalities in the neuroimaging of headache patients was 8.86% (95% confidence interval: 5.12–15.33%). Subsequently, diverse subgroup analyses were performed based on the detection method, headache type, study type, study region, age group, and disease type. CONCLUSION: The present findings indicate that limited neuroimaging methods should be carefully considered for headache diagnostic purposes when there are red flag symptoms. Limitations and suggested directions for future studies on neuroimaging in headache patients are described.
Diagnosis
;
Headache
;
Humans
;
Magnetic Resonance Imaging
;
Methods
;
Neuroimaging
;
Patient Selection
;
Prevalence
;
Tomography, X-Ray Computed
6.Tobacco Use in Korea: Current Epidemiology and Public Health Issues
Jong Eun PARK ; Woo Min JEONG ; Ye Jin CHOI ; So Young KIM ; Kyoung Eun YEOB ; Jong Hyock PARK
Journal of Korean Medical Science 2024;39(45):e328-
Tobacco control efforts in Korea began nearly three decades ago with the enactment of the National Health Promotion Act in 1995. Monitoring smoking prevalence is crucial for evaluating the effectiveness of tobacco control measures, as reductions in smoking rates reflect the impact of anti-smoking policies. This review aims to provide an updated overview of the epidemiology of tobacco use in Korea, outline the nation’s advancements in tobacco control, and emphasize emerging challenges in tobacco use. The data sources included statistics and reports from the World Health Organization (WHO) and the Organization for Economic Cooperation and Development (OECD), the Korea National Health and Nutrition Examination Survey, as well as various national statistics and reports on tobacco use and control in Korea.Over the past quarter-century, there was a notable 49.6% reduction in the prevalence of cigarette smoking among Korean adults, with a particularly pronounced decline among men (1998: 66.3% vs. 2022: 30.0%; a 54.8% decrease). However, the reduction among women was more modest, with only a 1.5 percentage point decrease (1998: 6.5% vs. 2022: 5.0%; a 23.1% decrease), and an increase in smoking prevalence was observed among women in their 20s and 30s. Overall use of any tobacco product, including cigarettes, heated tobacco products, electronic nicotine delivery systems, and others, was 6.6 percentage points higher among males and 2.2 percentage points higher among females compared to cigarette smoking alone.In 2019, there were 58,036 deaths attributed to direct smoking in Korea, with an estimated socioeconomic cost of smoking amounting to 12,191.3 billion Korean won. Furthermore, critical issues in tobacco use persist in Korea, including significant disparities in tobacco use related to age, gender, and disability, the growing use of novel tobacco and nicotine products among adolescents and younger adults, and regulatory blind spots. The reduction in smoking rates in Korea reflects the impact of expanded tobacco control policies and public health initiatives. However, for Korea to advance to the next level in tobacco control policies, it is essential to implement the WHO Framework Convention on Tobacco Control’s MPOWER measures more thoroughly.
7.Tobacco Use in Korea: Current Epidemiology and Public Health Issues
Jong Eun PARK ; Woo Min JEONG ; Ye Jin CHOI ; So Young KIM ; Kyoung Eun YEOB ; Jong Hyock PARK
Journal of Korean Medical Science 2024;39(45):e328-
Tobacco control efforts in Korea began nearly three decades ago with the enactment of the National Health Promotion Act in 1995. Monitoring smoking prevalence is crucial for evaluating the effectiveness of tobacco control measures, as reductions in smoking rates reflect the impact of anti-smoking policies. This review aims to provide an updated overview of the epidemiology of tobacco use in Korea, outline the nation’s advancements in tobacco control, and emphasize emerging challenges in tobacco use. The data sources included statistics and reports from the World Health Organization (WHO) and the Organization for Economic Cooperation and Development (OECD), the Korea National Health and Nutrition Examination Survey, as well as various national statistics and reports on tobacco use and control in Korea.Over the past quarter-century, there was a notable 49.6% reduction in the prevalence of cigarette smoking among Korean adults, with a particularly pronounced decline among men (1998: 66.3% vs. 2022: 30.0%; a 54.8% decrease). However, the reduction among women was more modest, with only a 1.5 percentage point decrease (1998: 6.5% vs. 2022: 5.0%; a 23.1% decrease), and an increase in smoking prevalence was observed among women in their 20s and 30s. Overall use of any tobacco product, including cigarettes, heated tobacco products, electronic nicotine delivery systems, and others, was 6.6 percentage points higher among males and 2.2 percentage points higher among females compared to cigarette smoking alone.In 2019, there were 58,036 deaths attributed to direct smoking in Korea, with an estimated socioeconomic cost of smoking amounting to 12,191.3 billion Korean won. Furthermore, critical issues in tobacco use persist in Korea, including significant disparities in tobacco use related to age, gender, and disability, the growing use of novel tobacco and nicotine products among adolescents and younger adults, and regulatory blind spots. The reduction in smoking rates in Korea reflects the impact of expanded tobacco control policies and public health initiatives. However, for Korea to advance to the next level in tobacco control policies, it is essential to implement the WHO Framework Convention on Tobacco Control’s MPOWER measures more thoroughly.
8.Tobacco Use in Korea: Current Epidemiology and Public Health Issues
Jong Eun PARK ; Woo Min JEONG ; Ye Jin CHOI ; So Young KIM ; Kyoung Eun YEOB ; Jong Hyock PARK
Journal of Korean Medical Science 2024;39(45):e328-
Tobacco control efforts in Korea began nearly three decades ago with the enactment of the National Health Promotion Act in 1995. Monitoring smoking prevalence is crucial for evaluating the effectiveness of tobacco control measures, as reductions in smoking rates reflect the impact of anti-smoking policies. This review aims to provide an updated overview of the epidemiology of tobacco use in Korea, outline the nation’s advancements in tobacco control, and emphasize emerging challenges in tobacco use. The data sources included statistics and reports from the World Health Organization (WHO) and the Organization for Economic Cooperation and Development (OECD), the Korea National Health and Nutrition Examination Survey, as well as various national statistics and reports on tobacco use and control in Korea.Over the past quarter-century, there was a notable 49.6% reduction in the prevalence of cigarette smoking among Korean adults, with a particularly pronounced decline among men (1998: 66.3% vs. 2022: 30.0%; a 54.8% decrease). However, the reduction among women was more modest, with only a 1.5 percentage point decrease (1998: 6.5% vs. 2022: 5.0%; a 23.1% decrease), and an increase in smoking prevalence was observed among women in their 20s and 30s. Overall use of any tobacco product, including cigarettes, heated tobacco products, electronic nicotine delivery systems, and others, was 6.6 percentage points higher among males and 2.2 percentage points higher among females compared to cigarette smoking alone.In 2019, there were 58,036 deaths attributed to direct smoking in Korea, with an estimated socioeconomic cost of smoking amounting to 12,191.3 billion Korean won. Furthermore, critical issues in tobacco use persist in Korea, including significant disparities in tobacco use related to age, gender, and disability, the growing use of novel tobacco and nicotine products among adolescents and younger adults, and regulatory blind spots. The reduction in smoking rates in Korea reflects the impact of expanded tobacco control policies and public health initiatives. However, for Korea to advance to the next level in tobacco control policies, it is essential to implement the WHO Framework Convention on Tobacco Control’s MPOWER measures more thoroughly.
9.Tobacco Use in Korea: Current Epidemiology and Public Health Issues
Jong Eun PARK ; Woo Min JEONG ; Ye Jin CHOI ; So Young KIM ; Kyoung Eun YEOB ; Jong Hyock PARK
Journal of Korean Medical Science 2024;39(45):e328-
Tobacco control efforts in Korea began nearly three decades ago with the enactment of the National Health Promotion Act in 1995. Monitoring smoking prevalence is crucial for evaluating the effectiveness of tobacco control measures, as reductions in smoking rates reflect the impact of anti-smoking policies. This review aims to provide an updated overview of the epidemiology of tobacco use in Korea, outline the nation’s advancements in tobacco control, and emphasize emerging challenges in tobacco use. The data sources included statistics and reports from the World Health Organization (WHO) and the Organization for Economic Cooperation and Development (OECD), the Korea National Health and Nutrition Examination Survey, as well as various national statistics and reports on tobacco use and control in Korea.Over the past quarter-century, there was a notable 49.6% reduction in the prevalence of cigarette smoking among Korean adults, with a particularly pronounced decline among men (1998: 66.3% vs. 2022: 30.0%; a 54.8% decrease). However, the reduction among women was more modest, with only a 1.5 percentage point decrease (1998: 6.5% vs. 2022: 5.0%; a 23.1% decrease), and an increase in smoking prevalence was observed among women in their 20s and 30s. Overall use of any tobacco product, including cigarettes, heated tobacco products, electronic nicotine delivery systems, and others, was 6.6 percentage points higher among males and 2.2 percentage points higher among females compared to cigarette smoking alone.In 2019, there were 58,036 deaths attributed to direct smoking in Korea, with an estimated socioeconomic cost of smoking amounting to 12,191.3 billion Korean won. Furthermore, critical issues in tobacco use persist in Korea, including significant disparities in tobacco use related to age, gender, and disability, the growing use of novel tobacco and nicotine products among adolescents and younger adults, and regulatory blind spots. The reduction in smoking rates in Korea reflects the impact of expanded tobacco control policies and public health initiatives. However, for Korea to advance to the next level in tobacco control policies, it is essential to implement the WHO Framework Convention on Tobacco Control’s MPOWER measures more thoroughly.
10.Clinical Characteristics and Severity of Respiratory Syncytial Virus Infection in Korean Children during the Post-COVID-19Pandemic Period
Ye Eun KIM ; Dayun KANG ; Ji Soo PARK ; Eun Hwa CHOI ; Ki Wook YUN
Infection and Chemotherapy 2024;56(1):83-87
We aimed to evaluate the clinical features of respiratory syncytial virus (RSV) infection and risk factors for severe RSV disease among Korean children in 2022/2023. A total of 235 children were identified, and 84.3% were hospitalized. Patients under 3 months and 2 years of age accounted for 20.9% and 54.5%, respectively. Pneumonia was diagnosed in 40.9% of children and bronchiolitis in 23.8%. Respiratory support and intensive care were required in 43.4% and 7.7% of patients, respectively. Haemophilus influenzae nasopharyngeal colonization and the presence of underlying disease showed a significant correlation with severity indicators. The clinical impact of RSV infection was high on infants and toddlers, even those having no underlying disease or not being indicated for palivizumab.